Organisational barriers to thrombolysis treatment of acute ischaemic stroke
- 12 September 2007
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (11), 2833-2839
- https://doi.org/10.1185/030079907x242557
Abstract
Background: Intravenous thrombolysis with fibrinolytic drugs such as alteplase is not implemented widely in any country although the treatment is both effective and cost-effective in selected patients within a 3-h window after acute ischaemic stroke. The purpose of the present study was to describe the organisational barriers to delivery of thrombolysis for acute ischaemic stroke with special regard to the Danish healthcare system. Method: Systematic and unsystematic searches of medical, economic and grey literature on organisational barriers to thrombolysis treatment were performed in Cochrane, PubMed, EMBASE, Cinahl, Econlit, NHS EED, SvedMed+ and the Health Technology Assessment (HTA) database. The search periods were 1996-2006. Findings: Three main types of literature on organisational barriers were found: medical literature including HTA reports on barriers related to the 3-h window, economic literature on barriers related to the lack of capacity to provide the treatment on a 24-h basis, and grey literature/policy papers on standards and demands to the hospitals and healthcare systems who implements the treatment. Conclusion: Information on organisational barriers can be extracted from different types of literature (medical, economic and grey literature/policy papers), but organisational barriers are most often not the primary study objective in the relevant literature. This review showed a broad spectrum of possible organisational barriers to the delivery of thrombolysis treatment of acute ischaemic stroke.Keywords
This publication has 9 references indexed in Scilit:
- Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic StrokeStroke, 2007
- Comparison of Tissue Plasminogen Activator Administration Management Between Telestroke Network Hospitals and Academic Stroke CentersStroke, 2006
- Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United StatesStroke, 2005
- Intravenous Thrombolysis for Acute Ischaemic Stroke: Preliminary Experience with Recombinant Tissue Plasminogen Activator in the UKCerebrovascular Diseases, 2005
- Alternative Strategies for Stroke CareStroke, 2004
- Organization of Medical Care in Acute Stroke: Importance of a Good NetworkCerebrovascular Diseases, 2003
- Thrombolysis for acute stroke in the United KingdomAge and Ageing, 2002
- A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHSHealth Technology Assessment, 2002
- Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic StrokePharmacoEconomics, 2001